Clarity In-Licenses Prostate Cancer Agent and Provides Update on Patent Portfolio
Sydney, Australia 6 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has successfully in-licensed a patent application on a Prostate Specific Membrane Antigen (PSMA) targeting agent for imaging and treating prostate cancer from the University of Melbourne. Clarity is also pleased to…